glp-1 news today cardiovascular outcomes 2025 november Frontiers GLP-1s Could Improve Heart Health

O., Fabiyi, O

Nair, V

Access provider messaging and lifestyle content through app

Timing Approximately 45 minutes before anticipated sexual activity

The new indication could give Novo Nordisk a boost against rivals in the GLP-1 agonist class, including Eli Lilly, whose dual GIP/GLP-1 agonist Mounjaro (tirzepatide) competes in the diabetes category and is in a phase 3 trial (TREASURE-CKD) looking at a CKD indication in people with obesity, with and without diabetes

Epitalon's value proposition is more specific: it is the only intervention with direct telomerase activation data in human somatic cells, targeting a hallmark that NAD+ does not reach